Cite
HARVARD Citation
van den Bent, M. et al. (2021). Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet oncology. 22 (6), pp. 813-823. [Online].